Alternatives to time-consuming, error-prone operations promise to reduce vaccine manufacturing costs and improve facility flexibility.
Leonard Mestrandrea
Advertisement
LeonardMestrandrea is principal of Mestrandrea Consulting LLC.
Articles by Leonard Mestrandrea
Advertisement
Latest Updated Articles
Moving to Closed Systems for Aseptic ProcessingNovember 15th 2017
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
4
The BioPharm Brief: Base Editing Hits Its Mark in Sickle Cell, a Phase 3 Win in Sjögren’s, and Off-the-Shelf CAR-T in Lupus
5